Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 27881 trials
Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program
NCT06115876
Recruiting
Conditions Diabetes Mellitus Type 2, Diabetes Melli...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Kuwait and the Gulf Region lack large longitudinal studies that identify risk factors dictating the onset of prediabetes and the progression to diabetes. The Kuwait Diabetes Epidemiology Program (KDEP), previously carried out at Dasman Diabetes Institute, was designed to develop a research dataset providing a random sampling of the Kuwaiti population. The dataset contained primarily epidemiology data for healthy, prediabetic and diabetic individuals; and was designed to serve as a resource for research and prevention programs on obesity, diabetes, and metabolic syndrome. The KDEP data supported research studies at DDI to delineate risk factors for metabolic disease from the views of genetics, biochemistry, immunology and epidemiology. One of the main limitations of the KDEP study was that it only captured a cross-sectional view of the participants in terms of diabetes status as well as lack of extensive phenotyping. In the current study, the investigators aim to perform a follow up on the non-diabetic KDEP cohort participants to enrich it with detailed physiological, genetic, biochemical and environmental data and thereby to establish an association between the development of diabetes and multidimensional risk factors. the investigatorswill also recruit family members of the KDEP and RA2010-005 participants as well as others with family history of diabetes to better identify familial patterns in risk factors. The outcome of this effort will immediately serve as a scientific baseline for developing prevention strategies for the control and management of obesity, diabetes and associated complications such as cardiovascular disease. Given the magnitude of the social and economic burden of diabetes on the Kuwaiti population, longitudinal data from the KDEP Follow-up study should play an important role in establishing the incidence of T2D progression in non-diabetic participants that were enrolled in the initial study as well as of progression to diabetes complications. This will have a positive impact on the population by providing clinicians with data to better target their patient management and by supporting policy and decision-makers in developing comprehensive health promotion programs to control these diseases at the national level.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Conversion to Diabetes (5 years)
  • Conversion to Pre-Diabetes (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-23
Completion: 2027-05-23
Eligibility
Age: 21 Years
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dasman Diabetes Institute
Contact Information
Study Contact:
Mohamed Abu-farha, PhD
+96560660804
mohamed.abufarha@dasmaninstitute.org
Fahd Al-Mulla, MD, PhD
2224 2999
fahd.almulla@dasmaninstitute.org
Interventions
N/A
Study Locations (1 sites)
Dasman Diabetes Institute, Kuwait City, 40000 Kuwait
Eligibility Criteria
Inclusion Criteria: People who participated in the original KDEP study. People with prediabetes. Type 2 Diabetes patients. Exclusion Criteria: People are unwilling to sign the consent form. Pregnant women.
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
NCT07106879
Recruiting
Conditions Cardiovascular Diseases, Metabolic Syndr...
Phase Not Applicable
Enrollment 7000
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Blood Work — Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.

Primary Outcomes

  • Number of participants who express interest in industry-sponsored clinical research (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-30
Completion: 2030-12-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 7000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clindove Research LLC
Principal Investigators:
  • Nelly Cohen, MD (PRINCIPAL_INVESTIGATOR) - Clindove Research LLC
Contact Information
Study Contact:
Nelly Cohen, MD
516-518-3239
study@clindoveresearch.com
Interventions
  • Other: Blood Work — Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
Study Locations (1 sites)
Clindove Research LLC, Brooklyn, New York 11221 United States
Eligibility Criteria
Inclusion Criteria: * Any participant of age 18 years and over * Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures. Exclusion Criteria: * Pregnant or breastfeeding individuals * Individuals having severe cognitive impairment or inability to provide informed consent * Individuals having acute psychiatric emergencies requiring immediate intervention/hospitalization * Individuals who are currently participating in another research study that conflicts with pre-screening data collection * Individuals having known history of drug/alcohol misuse * Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.
Alpelisib Challenge Test (ACT)
NCT07778524
Recruiting
Conditions Insulin Resistance, Type 2 Diabetes, Obe...
Phase PHASE1
Enrollment 15
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test a potentially easier method for measuring how much insulin a person is capable of producing than the current gold-standard method, the "hyperglycemic clamp." Participants will come in for a two-day (overnight) visit in which they will first undergo a "hyperglycemic clamp," in which they receive an intravenous (into the vein) infusion of glucose (sugar) in order to measure the maximum amount of insulin their body produces in response. They will then consume a series of three standardized meals throughout the rest of the day. At 23:00, they will take a single dose of alpelisib, a drug that interferes within insulin's actions in the body. Then, the following morning, they will undergo a "Mixed Meal Tolerance Test" in which they consume a standardized liquid nutritional beverage and have blood drawn periodically before and during the test.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Alpelisib 300 mg — All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg tablets) at 23:00 on Study Day 1
  • Diagnostic Test: Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib — All participants will ingest standardized mixed meals of Nestlé BOOST Plus on the morning of Study Day 2 after taking alpelisib the previous evening
  • Diagnostic Test: Hyperglycemic clamp — All participants will undergo a two-hour hyperglycemic clamp procedure to measure pancreatic insulin reserve on the morning of Study Day 1, prior to taking alpelisib. This procedure involves an infusion of dextrose 20% solution.

Primary Outcomes

  • Correlation coefficient between clamp and ACT/MMTT (Up to 17 hours after dosing alpelisib)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-09-02
Completion: 2028-08-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pisa
Principal Investigators:
  • Joshua R Cook, MD, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Joshua R Cook, MD, PhD
2123052663
jrc2175@cumc.columbia.edu
Ishwari Nagnur
2123059336
imn2113@cumc.columbia.edu
Interventions
  • Drug: Alpelisib 300 mg — All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg tablets) at 23:00 on Study Day 1
  • Diagnostic Test: Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib — All participants will ingest standardized mixed meals of Nestlé BOOST Plus on the morning of Study Day 2 after taking alpelisib the previous evening
  • Diagnostic Test: Hyperglycemic clamp — All participants will undergo a two-hour hyperglycemic clamp procedure to measure pancreatic insulin reserve on the morning of Study Day 1, prior to taking alpelisib. This procedure involves an infusion of dextrose 20% solution.
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-70 years * Able to understand wrifen and spoken English and/or Spanish * Body mass index of 18-45 kg/m2 (or 18-42 kg/m2 for those of Asian ancestry) * For Lean group: BMI 18.0-24.9 kg/m2 (or 18.0-22.9 kg/m2 for those of Asian ancestry) * For Overweight group: BMI 25.0-29.9 kg/m2 (or 23.0-27.4 kg/m2 for those of Asian ancestry) * For Obesity group: BMI 30.0-45.0 kg/m2 (or 27.5-42 kg/m2 for those of Asian ancestry) Exclusion Criteria: * Inability to provide informed consent in English or Spanish * Unwillingness to fast (except water) for up to 18 hours * Unwillingness not to get out of bed and to use bedpan/urinal to void for up to 15 hours * Documented weight change of ≥ 5.0% of baseline within the previous 3 months * Abnormal blood pressure * Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or * Diastolic blood pressure \< 55 mm Hg or \> 100 mm Hg * Abnormal resting heart rate \< 55 bpm or ≥ 110 bpm * Sinus tachycardia that has been extensively worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion * Sinus bradycardia between heart rates of 45 and 54 bpm may be permitted at the PI's discretion if in a clinically appropriate setting (e.g., toned athlete, taking beta blockers) * Abnormal (i.e., non-regular) heart rhythm detected on physical exam * Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant * Liver function abnormalities (either of the following) * Transaminases (AST or ALT) \> 3.0 x the upper limit of normal * Total bilirubin \> 1.25 x the upper limit of normal * Laboratory evidence of diabetes mellitus: * Hemoglobin A1c ≥ 6.5%, and/or * Fasting plasma glucose ≥ 126 mg dL-1 * Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential * Women currently pregnant * Women currently breastfeeding * History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes): * Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency * Plasma glucose ≥ 126 mg/dL after 8-h fast * Plasma glucose of ≥ 200 mg/dL at 2 h after ingestion of a 75-g glucose load * Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state * History of gestational diabetes mellitus within the previous 5 years * Use of most antidiabetic medications within the 90 days prior to screening * Exceptions: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening * Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease) * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary) * Atherosclerotic cardiovascular disease * Stable or unstable angina * Myocardial infarction * Ischaemic or hemorrhagic stroke * Peripheral arterial disease (claudication) * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) * History of percutaneous coronary intervention * Congestive heart failure (NYHA Class ≥ 2) * Severe valvular heart disease (e.g., aortic stenosis) * Pulmonary hypertension * Advanced or severe liver disease, including but not limited to: * Advanced liver fibrosis, as determined by non-invasive testing * Cirrhosis of any etiology * Autoimmune hepatitis or other rheumatologic disorder affecting the liver * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis) * Chronic liver infection (e.g., viral hepatitis, parasitic infestation) * Hepatocellular carcinoma * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease) * Psychiatric diseases causing functional impairment that: * Are or have been decompensated within 1 year of screening, and/or * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine) * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation * Bleeding disorders, including due to anticoagulation, or significant anemia (see above) * Active malignancy, or hormonally active benign neoplasm, except allowances for: * Non-melanoma skin cancer * Differentiated thyroid cancer (AJCC Stage I only) * Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above * Use of certain medications currently or within 30 days prior to screening: * Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for: * Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above (e.g., ACEi/ARB used for uncomplicated hypertension rather than for congestive heart failure, etc.) * Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted * History of certain weight-loss (bariatric) surgery, including: * Roux-en-Y gastric bypass * Biliopancreatic diversion * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months * Clinical concern for alcohol overuse based on chart review and/or by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females * Regular tobacco use (smoking more than 1 cigarette per week) or regular nicotine vaping (daily) * Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening * History of or ongoing febrile illness within 14 days of screening * Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data. * Known allergy/hypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy/hypersensitivity as judged by the investigator. * Concurrent enrollment in another clinical study of any investigational drug/biologic therapy within 5 half-lives of an investigational agent or biologic.
Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients
NCT02488733
Active, positions filled
Conditions Type 2 Diabetes Mellitus
Phase NA
Enrollment 30
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Bariatric surgery is efficient in both inducing adequate weight loss and the control of glycemia in obese patients affected by Type 2 Diabetes Mellitus (T2DM). Despite growing evidence suggesting that early performance of bariatric surgery on obese patients with T2DM offers the best opportunity to reach and maintain a remission of diabetes, no randomized clinical trials (RCT) have evaluated its efficiency in patients with new T2DM diagnosis. The aim of this RCT is to compare bariatric surgery, and in particular Laparoscopic Sleeve Gastrectomy (LSG), with conventional medical therapy (CMT) in patients with new T2DM diagnosis that are obese (Body Mass Index, BMI of between 30 and 42 Kg/m2), to be recruited at two Italian diabetology centres (Terni and Rome). The main objective of the present RCT is to investigate the efficacy of LSG as compared with CMT in inducing and maintaining both a resolution of T2DM (defined as HbA1c levels ≤6.0%, without active pharmacologic therapy or ongoing procedures) and the remission of T2DM through the evaluation of the criteria provided by the American Diabetes Association (ADA) at maximum follow-up of 6 years. The effects of the two treatments in terms of weight loss and the quality of life of the patient will also be taken into consideration. Any positive results of this study will include preventing microvascular and macrovascular complications connected with diabetes, without the necessity to take medication, and at the same time the loss of excess body weight and improved quality of life (QOL).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: LSG — In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
  • Drug: CMT — CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .

Primary Outcomes

  • Rate of patients achieving diabetes resolution (Assessed up to 1 year after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2015-12
Completion: 2028-03
Eligibility
Age: 20 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliera Santa Maria, Terni, Italy
Collaborators: Ethicon Endo-Surgery
Principal Investigators:
  • Stefano Trastulli, MD (PRINCIPAL_INVESTIGATOR) - Azienda Ospedaliera Santa Maria di Terni
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Procedure: LSG — In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
  • Drug: CMT — CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Study Locations (2 sites)
Ospedale Sandro Pertini, Rome, Italy
Azienda Ospedaliera Santa Maria, Terni, 05100 Italy
Eligibility Criteria
Inclusion Criteria: 1. No contraindication for laparoscopic surgery or general anaesthesia. 2. Age ≥20 and ≤65 years. 3. BMI of between 30 and 42 kg/m2. 4. Documented new diagnosis of Type 2 Diabetes Mellitus obtained according to the following American Diabetes Association parameters: fasting blood glucose ≥ 126 mg/dl (7.0 mmol/l) and/or HbA1c ≥ 6.5% and no more than 8 months from enrollment in the study. Exclusion Criteria: 1. Previous bariatric surgery or major abdominal surgery. 2. Patients with T2DM diagnosis treated with insulin. 3. Evidence of complications connected to diabetes at any stage (diabetic retinopathy, diabetic nephropathy/microalbuminuria, cardiovascular disease or neuropathy). 4. Cardiovascular diseases such as ischemia / coronary artery disease, arrhythmia, peripheral vascular diseases, congestive heart failure, history of heart attacks. 5. Kidney diseases including nephro-vascular hypertension, stenosis of the renal artery or chronic renal insufficiency. 6. Pregnancy 7. Diagnosis of psychiatric illness (including dementia, severe depression, history of suicide attempts) or abuse of alcohol or drugs in the previous 5 years.
Online Diabetic Foot Support Program- Care Kit
NCT06760416
Active, positions filled
Conditions Diabetes Mellitus, Diabetic Foot Ulcer, ...
Phase NA
Enrollment 62
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this project is to examine the effects of the online diabetic foot support program (DiaFootSuP) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, HbA1c, etc.).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Nursing Education — 5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit

Primary Outcomes

  • The 5-item Diabetes Foot Care Knowledge Scale (two week)
  • Foot Self Care Observation Guide (two week)
  • Diabetic Foot Care Self Efficacy Scale (two week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2024-11-01
Completion: 2025-03-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 62 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Merve GÃnbaAY
Collaborators: The Scientific and Technological Research Council of Turkey
Principal Investigators:
  • Merve M GÜNBAŞ, Msc. Phd. (PRINCIPAL_INVESTIGATOR) - Dokuz Eylul University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: Nursing Education — 5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit
Study Locations (1 sites)
Dokuz Eylül University, Izmir, Buca 35380 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older, Individuals diagnosed with type 2 diabetes, Patients who have had diabetic foot ulcers and have healed, Can read and write Turkish, No visual, hearing, perception and any physical disability, Physical, mental and cognitive competence to participate in self-care activities, Able to use technological products (able to use computers, tablets and smartphones), Individuals who voluntarily agree to participate in the study will constitute the sample Exclusion Criteria: * Patients with active diabetic foot ulcers, Individuals who cannot read or write, Individuals who cannot use technological devices, Individuals who do not want to participate in the study
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
NCT07730567
Not yet recruiting
Conditions Hyperlipidemia, Diabete Type 2
Phase PHASE1
Enrollment 44
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Treatment A(AD-236A) — AD-236A Oral Tablet
  • Drug: Treatment B(AD-236B) — AD-236B Oral Tablet
  • Drug: Treatment C(AD-236A+AD-236B) — AD-236A+AD-236B Oral Tablet

Primary Outcomes

  • 1. Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss) (pre-dose (0hour) to 24 hours post-dose)
  • Maximum concentration of drug in plasma at steady state (Cmax,ss) (pre-dose (0hour) to 24 hours post-dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Not yet recruiting
Start Date: 2026-07-29
Completion: 2026-09-26
Eligibility
Age: 19 Years
Sex: ALL
Volunteers: true
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Addpharma Inc.
Contact Information
Study Contact:
Heeyoung Hong
821094710619
hyhong@addpharma.co.kr
Interventions
  • Drug: Treatment A(AD-236A) — AD-236A Oral Tablet
  • Drug: Treatment B(AD-236B) — AD-236B Oral Tablet
  • Drug: Treatment C(AD-236A+AD-236B) — AD-236A+AD-236B Oral Tablet
Study Locations (1 sites)
H+ Yangji Hospital, Seoul,, Seoul, 08779 South Korea
Eligibility Criteria
Inclusion Criteria: * Healthy adult volunteers aged ≥19 and ≤55 years at the time of the screening visit * Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
NCT05074732
Recruiting
Conditions Schizophrenia, Forensic Psychiatry, Outc...
Phase Not Applicable
Enrollment 350
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service. The study will have a prospective, observational, longitudinal design which will permit the evaluation of benefit over time for individual patients, groups of patients and the evaluation of the benefit in terms of service based outcomes of the redevelopment of a complete National Forensic Mental Health Service e.g. effects on waiting list times, length of stay. The study will systematically evaluate multiple domains of recovery in a complete National Forensic Service, including patients' physical health, mental health, offending behaviours and social and occupational functioning.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Length of stay in the secure forensic hospital setting. (5 years)
  • Recovery from psychosis (5 years)
  • Reduction in violence (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-12-01
Completion: 2027-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Health Service Executive, Ireland
Principal Investigators:
  • Mary Davoren, M.D. (PRINCIPAL_INVESTIGATOR) - Trinity College University of Dublin
Contact Information
Study Contact:
Mary Davoren, M.D.
0035312157401
davorem@tcd.ie
Harry G Kennedy, M.D.
0035312157400
kennedh@tcd.ie
Interventions
N/A
Study Locations (1 sites)
National Forensic Mental Health Service, Central Mental Hospital, Dublin, D14 W0V6 Ireland
Eligibility Criteria
Inclusion Criteria: * Admitted to the National Forensic Mental Health Service (NFMHS) Ireland after 1st December 2019 until 7 years after the transfer of the National Service to the newly developed complete National Forensic Service at Portrane, North Dublin, Ireland. Exclusion Criteria: * This study comprises a complete cohort of admissions to the NFMHS. All adult patients admitted during the time period will be included in the study, regardless of their length of stay.
Peel Family Diabetes Prevention Program
NCT07675551
Recruiting
Conditions Diabete Type 2
Phase NA
Enrollment 280
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-08
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this Hybrid Type 2 effectiveness-implementation pilot randomized controlled trial is to assess the feasibility and preliminary effectiveness of a community-based wellness coaching intervention to prevent type 2 diabetes (T2D) among South Asian (SA) and Black African and Caribbean (BAC) communities in the Peel region of Ontario, Canada. The study evaluates the impact of the intervention on reducing diabetes risk and related intermediate outcomes, including biomarkers, anthropometric measures, well-being, knowledge, health behaviours, and family-level outcomes in participating family dyads. Each SA and BAC family dyad will consist of a primary adult family caregiver aged 18 years or older, who does not have T2D and is not taking pharmacological treatment for blood glucose reduction, and a youth aged 14 to 24 years residing in the same household. The study aims to generate preliminary evidence on both the implementation and effectiveness of the intervention over a 12-month period. Participant dyads of each ethnocultural group (SA and BAC) will be randomly assigned to either the intervention or control arm. During the first six months, participants in the intervention arm will receive biweekly health and wellness coaching delivered by trained community-based coaches, optional group coaching sessions with other participants, weekly motivational messages, and an educational T2D prevention booklet. Participants in the control arm will receive only the educational T2D prevention booklet. Implementation and effectiveness outcomes will be assessed using a mixed-methods approach, integrating qualitative and quantitative data collected at baseline and at the 6- and 12-month post-randomization time points. This approach is intended to generate comprehensive, preliminary evidence on both the implementation and effectiveness components of the health and wellness intervention. Quantitative and mixed-methods analyses will be conducted to provide an integrated understanding of the implementation and effectiveness outcomes studied. Findings from this pilot trial will inform the design of larger, definitive studies to better assess impact and guide future escalation and/or adaptation. Results will be disseminated in multiple formats and tailored to diverse audiences, including community partners, local communities, academics, researchers, and decision-makers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Family Dyad Health and Wellness Coaching Session — Biweekly health and wellness coaching sessions (in-person or virtual) for type 2 diabetes, provided by trained community-based coaches. The maximum session length will be 30 minutes, with no mandatory minimum. Coaches will also share a short weekly motivational message, delivered to participants' phones or emails, depending on preferences. The intervention group participants may join an optional monthly group-based health and wellness coaching session with other program participants. Group sessions will be approximately 2 hours in length.
  • Behavioral: Educational Material — A printed or digital educational booklet on type 2 diabetes (T2D) prevention. The booklet contains information related to the causes and signs of T2D, diet and physical activity engagement activities, mental well-being enhancement and stress management, strategies to set up positive lifestyles and behavioural change, along with a list of local health and social support services that may be used to further promote overall well-being and support T2D risk reduction.

Primary Outcomes

  • Implementation Outcome: Intervention Acceptability (Six months post-randomization and twelve months post-randomization)
  • Implementation Outcome: Intervention Appropriateness (Six months post-randomization and twelve months post-randomization)
  • Implementation Outcome: Intervention Reach (Baseline)
  • Implementation Outcome: Intervention Adoption (Uptake) (Six months post-randomization and twelve months post-randomization)
  • Implementation Outcome: Intervention Availability (Six months post-randomization and twelve months post-randomization)
  • Implementation Outcome: Intervention Fidelity (Six months post-randomization, and twelve months post-randomization)
  • Effectiveness Outcome: T2D Risk (Baseline, six months post-randomization and twelve months post-randomization)
  • Effectiveness Outcome: Overall Quality of Life (Baseline, six months post-randomization, and twelve months post-randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-20
Completion: 2028-03-31
Eligibility
Age: 14 Years
Sex: ALL
Volunteers: true
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Trillium Health Partners
Collaborators: Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Principal Investigators:
  • Ian Zenlea, MD, MPH (PRINCIPAL_INVESTIGATOR) - Institute for Better Health, Trillium Health Partners, Mississauga.
Contact Information
Study Contact:
Cilia Mejia-Lancheros (Study Research Lead), RN, MPH, Msc. GHP, PhD
437 216 6209
Cilia.Mejia-Lancheros@thp.ca
Hamna Khan, MPP
437-231-6951
hamna.khan@thp.ca
Interventions
  • Behavioral: Family Dyad Health and Wellness Coaching Session — Biweekly health and wellness coaching sessions (in-person or virtual) for type 2 diabetes, provided by trained community-based coaches. The maximum session length will be 30 minutes, with no mandatory minimum. Coaches will also share a short weekly motivational message, delivered to participants' phones or emails, depending on preferences. The intervention group participants may join an optional monthly group-based health and wellness coaching session with other program participants. Group sessions will be approximately 2 hours in length.
  • Behavioral: Educational Material — A printed or digital educational booklet on type 2 diabetes (T2D) prevention. The booklet contains information related to the causes and signs of T2D, diet and physical activity engagement activities, mental well-being enhancement and stress management, strategies to set up positive lifestyles and behavioural change, along with a list of local health and social support services that may be used to further promote overall well-being and support T2D risk reduction.
Study Locations (2 sites)
Wellfort Community Health Services, Brampton, Ontario L6T 3J1 Canada
Punjabi Community Health Services (PCHS), Brampton, Ontario L6T 3T6 Canada
Eligibility Criteria
Inclusion Criteria: Dyad participants will consist of a self-identified primary family caregiver aged 18 years or older and a youth family member aged 14 to 24 years at the time of study entry. The primary family caregiver will serve as the primary (index) research participant for the dyad and should have the following inclusion criteria: 1. Self-identifies as either South Asian or Black, African and Caribbean. 2. Lives in the Peel Region (Mississauga, Brampton or Caledon), Ontario, Canada. 3. Be 18 years or older and have a youth child aged 14 to 24 years in the household who is willing and consents to participate. AND 4. Have no medical diagnosis (self-reported) of diabetes. 5. Have no medical diagnosis (self-reported) of prediabetes that requires any medical or pharmacological treatment. Have a blood-based sugar greater than or equal to 6.5 measured through the hemoglobin A1c test using a finger prick at the pre-enrollment assessment visit. AND 6. The family dyad (family caregiver and youth) must be proficient in English (reading, writing, and speaking), as English will be the primary language used for the participation eligibility, implementation, delivery, and evaluation of the intervention. Exclusion Criteria for family dyad: 1. Do not meet all the criteria above. 2. A medical condition or health professional has advised them not to engage in physical activity of any type, or they are following a specific diet. 3. Cannot give informed consent to participate voluntarily in the intervention and study.
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473
Recruiting
Conditions Major Depressive Disorder (MDD)
Phase PHASE2
Enrollment 118
Locations 22 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-08-24
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: DT-101 — DT-101
  • Drug: Placebo — Placebo

Primary Outcomes

  • Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 56 (from enrolment to day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-14
Completion: 2027-05
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Draig Therapeutics Ltd
Contact Information
Study Contact:
Aeron-1 Clinical Team
+44(0)2920028450
info@draigtherapeutics.com
Interventions
  • Drug: DT-101 — DT-101
  • Drug: Placebo — Placebo
Study Locations (22 sites)
Draig Clinical Site, Phoenix, Arizona 85013 United States
Draig Clinical Site, Little Rock, Arkansas 72211 United States
Draig Clinical Site, Bellflower, California 90706 United States
Draig Clinical Site, Costa Mesa, California 92626 United States
Draig Clinical Site, Lafayette, California 94549 United States
Draig Clinical Site, Hialeah, Florida 33016 United States
Draig Clinical Site, Orlando, Florida 32803 United States
Draig Clinical Site, Orlando, Florida 32807 United States
Draig Clinical Site, Tampa, Florida 33607 United States
Draig Clinical Site, Tampa, Florida 33613 United States
Eligibility Criteria
Inclusion Criteria: * The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent * Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent. * Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022). Exclusion Criteria: * Pregnant or breastfeeding or plans to become pregnant during the study. * Unstable medical condition or unstable chronic disease. * Significant neurological abnormality. * History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening. * History of seizure. * In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Neuromodulation of Mood Switch Circuitry in Bipolar Disorder
NCT07680153
Not yet recruiting
Conditions Bipolar Disorder (BD), Bipolar 1 Depress...
Phase PHASE4
Enrollment 62
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-08-24
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD. Investigators in this study will use a technique called repetitive transcranial magnetic stimulation, or rTMS. It uses non-invasive magnetic pulses delivered to the scalp to stimulate specific areas of the brain. rTMS is already used to treat depression, and investigators are now studying whether it can be made even more effective for people with bipolar disorder by precisely targeting an individualized brain region for each participant. Participants in this study will receive two courses of rTMS, one active and one placebo (called "sham"), in a randomized order so investigators can directly compare the effects. Before treatment, investigators will use brain scans (MRI) to create a personalized map of each participant's brain activity. This lets investigators identify the exact stimulation target most likely to influence the brain circuits involved in BD mood shifts. Investigators will track mood symptoms closely throughout the study to measure what changes. Investigators believe that depression in BD is partly driven by disrupted communication between two brain regions involved in processing what feels important or rewarding. Investigators want to find out whether rTMS can restore that communication and whether doing so leads to measurable improvements in depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: MagVenture MagPro TMS system — TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting. Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
  • Device: Sham Stimulation — An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation. The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation. Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).

Primary Outcomes

  • Change from Baseline to 1-Week Post-rTMS in Montgomery-Asberg Depression Rating Scale (MADRS) Score (Baseline to 1-week post-rTMS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Not yet recruiting
Start Date: 2026-07
Completion: 2031-12
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: BD2 LLC
Principal Investigators:
  • Immanuel Elbau, MD, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Interventions
  • Device: MagVenture MagPro TMS system — TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting. Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
  • Device: Sham Stimulation — An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation. The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation. Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Adults of all genders aged 18-70 at the time of screening. 3. Diagnosis of Bipolar Disorder (by DSM-V criteria) 4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \>= 14 or as determined by expert clinician). 5. Not currently taking medications for BD OR on a stable dose of medication for at least 1 month prior to screening and plans to remain off medications OR on this stable dose for the duration of participation. 6. Access to psychiatric care before, during, and after completion of the study. 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. 8. Proficiency in English sufficient to complete assessments and follow study procedure instructions. 9. Stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: 1. Imminent risk of suicide. 2. Presence of a primary DSM-5 diagnosis other than bipolar disorder (BD-I or BD-II), or a current comorbid psychiatric disorder that, in the opinion of the investigators, would confound outcome assessment or interfere with safe participation. 3. History of seizures or any condition / concurrent medication that could notably lower seizure threshold. 4. Met criteria for any significant substance use disorder (by DSM-V criteria) in the 6 months prior to screening. 5. History or presence of significant neurological disorder (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy). 6. History or presence of significant heart condition (e.g., recent myocardial infarction, congestive heart failure \> stage 2, angina pectoris, bradycardia or tachycardia at the baseline assessment, uncontrolled hypertension). 7. MRI contraindication, including presence of foreign metal bodies or implants, implanted or conductive objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), permanent make-up. 8. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation. 9. Abnormal bloodwork for electrolytes, thyroid, or liver function. 10. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures.
Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems
NCT07594730
Not yet recruiting
Conditions Depression Disorders, ADHD, Substance Ab...
Phase NA
Enrollment 1600
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-08-24
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test the efficacy of brief video interventions parental internalized stigma and stigma-related outcomes (e.g., treatment intentions, caregiver burden, secrecy) among parents (ages 25-50) of children ages 6-18 with depression, ADHD, or substance use problems. Timely identification and treatment of mental health problems in youth is a public health priority. However, many youth do not receive treatment, and stigma has been identified as the primary barrier to help-seeking. Parents experience stigma related to their children having mental health problems, which has been associated with reduced help-seeking and increased parental distress. Prior experiments have found brief video-based interventions (BVIs), 1-2 minute videos similar to those viewed by youth on social media platforms, based on the principle of "social contact" with individuals affected by a stigmatized condition, effective in reducing mental health stigma and increasing help-seeking. In this 4-arm RCT, the investigators will recruit parents aged 25-50 using an online crowdsourcing platform, to test the efficacy of BVIs featuring a personal parent narrative of their experience with their child's a) depression, b) ADHD, or c) substance use, or d) a control condition that provides general written psychoeducational information without social contact.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Other: Brief video — Brief video about depression (arm 1), ADHD (arm 2), or substance use (arm 3)

Primary Outcomes

  • Parental Internalized Stigma of Mental Illness scale (PISMI) (Immediately after viewing video, 30 days after intervention)
  • Attitudes Toward Seeking Professional Psychological Help Scale-Short Form (adapted) (Immediately after viewing video, 30 days after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-07-06
Completion: 2026-09-06
Eligibility
Age: 25 Years
Sex: ALL
Volunteers: true
Enrollment: 1600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: New York State Psychiatric Institute
Collaborators: Columbia University
Principal Investigators:
  • Doron Amsalem, MD (PRINCIPAL_INVESTIGATOR) - Columbia University; New York State Psychiatric Institute
Contact Information
Study Contact:
Doron Amsalem, MD
929-404-8802
doron.amsalem@nyspi.columbia.edu
Timothy Becker, MD
914-997-5203
tdb2143@cumc.columbia.edu
Interventions
  • Other: Brief video — Brief video about depression (arm 1), ADHD (arm 2), or substance use (arm 3)
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify as English Speaking * Live in the US * Ages 25-50 * Have a child 6-18 years old with either depression, ADHD, or a substance use problem Exclusion Criteria: * Do not speak English * Do not live in the US * \<25 or \>50 * Do not have a child between ages 6-18 with depression, ADHD, or a substance use problem
Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity
NCT07116460
Recruiting
Conditions Asthma Attack, Lung Function, Airway Inf...
Phase NA
Enrollment 55
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This project will investigate the effectiveness of HEPA air cleaners in reducing indoor air pollution and improving asthma morbidity in children living in East Harlem, New York City (NYC). The study will be conducted over a 2-year period. Columbia University and Little Sisters of the Assumption Family Health Service (LSAFHS) will conduct an intervention study to evaluate the efficacy of using a cost-effective high-capacity high efficiency particulate air (HEPA) filter air cleaner to reduce airborne particulate matter (PM) in the homes of children with asthma and to reduce their asthma morbidity. The study will take place in East Harlem, a low-income neighborhood with high asthma prevalence. It will build on findings from prior Housing and Urban Development Lead and Healthy Homes Technical Studies (HUD LHHTS)-funded research, the experience of LSAFHS installing air cleaners in the homes of asthmatic children, and recent findings demonstrating the effectiveness of home air cleaners in reducing asthma morbidity. The investigators hypothesize that the cost-effective single air cleaner will substantially reduce PM exposure in the homes of asthmatic children and reduce airway inflammation and asthma morbidity. This study will use cutting-edge air sampling technology to continuously quantify and characterize indoor air pollutants in the home for one year, verify and incentivize compliance, and conduct repeated exhaled nitric oxide and pulmonary function tests before and throughout the year after the intervention. This cost-effective intervention can be easily and quickly implemented in homes in low-income, urban communities and easily transferred between homes if families move.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Austin Air Cleaner — The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.

Primary Outcomes

  • Fractional Exhaled Nitric Oxide (FeNO) (1 week before, immediately before, two weeks after, and one year after the air cleaner is turned on.)
  • Forced Expiratory Volume in 1 Second/ Forced Vital Capacity (FEV1/FVC) Ratio (1 week before, immediately before, two weeks after, then once a month (up to 1 year) after the air cleaner is turned on.)
  • Number of Attacks of Wheezing (Once per month for up to 12 months after the air cleaner is turned on)
  • Number of Emergency Department (ED) Visits (12 months after the air cleaner is turned on)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-30
Completion: 2028-04
Eligibility
Age: 7 Years
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: Little Sisters of the Assumption Family Health Service
Principal Investigators:
  • Matthew S Perzanowski, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Matthew S Perzanowski, PhD
(212) 305-3465
mp2217@cumc.columbia.edu
Luis M Acosta, MD
(212) 305-6925
la181@cumc.columbia.edu
Interventions
  • Device: Austin Air Cleaner — The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.
Study Locations (1 sites)
Columbia University Irving Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Age 7-18 years * Asthma symptoms in the past 4 weeks * Resident in lower-income housing in NYC Northern Manhattan and South Bronx Exclusion Criteria: * Inability to successfully perform spirometry maneuver or FeNO test * Family planning to move in the next year
Optimising Inhaler Technique and Asthma Self-management in Children and Young People
NCT06531096
Active, positions filled
Conditions Asthma in Children
Phase NA
Enrollment 45
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this randomised pilot study is to explore ways to optimise a care pathway that results in children and young people with asthma being better trained in the basics of asthma care and better able to apply self-management at the earliest possible stage. This will involve comparing a novel augmented teaching method (Video directly observed therapy (v-DOT)) with standard training in achieving and sustaining mastery of inhaler and nasal spray technique and the understanding of a personalised asthma action plan (PAAP).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: v-DOT — Video directly observed therapy

Primary Outcomes

  • Mastery of technique (Once mastery of technique established which is defined as 3 consecutive days of correct technique.)
  • Technique score (Baseline and 1, 3 and 6 months after achieving technique mastery)
  • Personalised asthma action plan (PAAP) understanding. (Baseline and 1, 3 and 6 months after achieving technique mastery)
  • Recruitment rates (Through study recruitment, an average of 1 year.)
  • Retention rates (At study completion for all participants, up to 2 years.)
  • Qualitative interviews to identify barriers to using video directly observed therapy (v-DOT) (3-6 months after achieving mastery of technique.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2022-11-17
Completion: 2024-09-01
Eligibility
Age: 1 Year
Sex: ALL
Volunteers: false
Enrollment: 45 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Queen's University, Belfast
Principal Investigators:
  • Dara O'Donoghue, MD (PRINCIPAL_INVESTIGATOR) - Queen's University, Belfast
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: v-DOT — Video directly observed therapy
Study Locations (1 sites)
Belfast Health and Social care trust, Belfast, BT12 6BA United Kingdom
Eligibility Criteria
Inclusion Criteria: * 1-15 years of age (up to 16th birthday) * Established asthmatic children (prescribed an inhaled corticosteroid preventer), who have been admitted or referred for paediatric ward review or attended A\&E with their 2nd acute wheeze episode within a 6-month period. * Established asthmatic children (prescribed an inhaled corticosteroid preventer), with inadequate control whom medical staff feel would benefit from further education. * 3rd viral induced wheezing episode within 6 months, in those already prescribed an inhaled corticosteroid preventer (but not formally 'asthma'). * English and non-English speaking children and young people will be eligible as we have access to translation services that are already utilised at our asthma clinics. Exclusion Criteria: * Children who have previously received intervention through the safe asthma discharge care pathway service. * \< 1 year of age. * Children and young people with cough but no wheeze. * Those children who are referred to paediatric asthma clinic or nurse led asthma clinic, where they have received teach back training on inhaler technique/nasal spray technique and PAAP training.
Feasibility of a Smartphone Application for Asthma Self-management
NCT05572177
Recruiting
Conditions Asthma Chronic
Phase NA
Enrollment 50
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The primary goal of this project is to determine the feasibility, acceptability, and adherence of a smartphone application for improving asthma self-management in a pilot randomized controlled trial (RCT). The app is specifically designed to appeal to adolescents. Adolescents with persistent asthma will be randomized to receive: 1) standard-of-care or 2) the self-management app in addition to standard-of-care. Feasibility will be assessed by the ability to recruit and retain subjects, technical barriers to implementation, and the appropriateness of the intervention among adolescents and providers. The acceptability of the intervention will be determined by appraising perceived usefulness, entertainment, and ease of use of the app. Adherence to usage of the app over a 6-month period will be assessed by examining the frequency of app usage and the features that were used, and the extent of data regarding self-management that was entered. A secondary objective is to obtain preliminary estimates of effectiveness of the app on clinical outcomes (ACT score, spirometry, CHSA-C, exacerbations, and medication adherence) relative to standard-of-care. It is hypothesized that the app will result in a high level of adherence and will be a feasible and acceptable intervention to improve self-management among adolescents with persistent asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Device Feasibility Masking/blinding: None

Interventions / Regimen

  • Device: Asthma SMART — The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.

Primary Outcomes

  • Recruitment rate (number recruited per month) (6 months)
  • Retention rate (proportion that complete the 6-month trial) (6 months)
  • Technical feasibility (percentage of screened population) (6 months)
  • Mean overall usability score obtained from the Health-ITUES (Assessed at the end of the 6 month trial)
  • Average app usage per day (6 months)
  • Adherence to app reminders (proportion of app reminders) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-26
Completion: 2025-07-31
Eligibility
Age: 12 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South Florida
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Amy Alman, PhD (PRINCIPAL_INVESTIGATOR) - University of South Florida
  • Marisa Couluris, DO (PRINCIPAL_INVESTIGATOR) - University of South Florida
  • Paul Rosen, PhD (PRINCIPAL_INVESTIGATOR) - University of Utah
Contact Information
Study Contact:
Dipti Karnani
813-974-5193
diptik@usf.edu
Nataliya Kuzmin
813-974-9157
Nataliyak@usf.edu
Interventions
  • Device: Asthma SMART — The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
Study Locations (1 sites)
University of South Florida, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * At least 12 and less than 18 years at enrollment * Established mild, moderate, or severe persistent asthma with a diagnosis verified by clinic physicians * Speak English * Not planning on moving out of the Tampa Bay area during the trial period * Must have a suitable iPhone or Android device available to use with the app Exclusion Criteria: * Having mental or other development disorder that may make self-management of a chronic condition difficult * Having other chronic lung disease or one or more of the following disorders including cystic fibrosis, neuromuscular disease, immunodeficiency or autoimmune disorders, blindness or severe vision impairment that may interfere with the ability to use the mobile app * Having participated in the app development phase of the funded project
Dosing of Steroids for Acute Asthma Given in the Emergency Department - a Pilot Randomised Feasibility Trial of Dexamethasone in Children
NCT07402707
Recruiting
Conditions Acute Asthma, Dexamethasone
Phase PHASE4
Enrollment 104
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Steroids given by mouth are an important first line treatment for children presenting with asthma attacks. Dexamethasone is the steroid used in some emergency departments (EDs) because of the need for a single dose and as it is well tolerated. The dose of dexamethasone in treating asthma attacks is not clearly established. This study compares two different doses of dexamethasone in children presenting with an asthma attack. Investigators will compare the effect of two different doses in reducing the need for a repeat prescription of steroids for an asthma attack in the 2 weeks after the first treatment. The investigators will also look at how often children attend the ED or their GP after being given treatment as well as the acceptability to parents and children. Although this study may provide an answer to the question of whether the different doses have the same effect, the investigators believe that a larger study will be needed to provide robust generalisable evidence, as well as to ensure that the outcomes are truly what matters to parents, children and healthcare professionals. This study will provide valuable information to enable a larger study to be undertaken.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: dexamethasone oral — The interventions are Dexamethasone, 0.3mg/kg versus 0.6 mg/kg

Primary Outcomes

  • Participant recruitment (7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-23
Completion: 2026-08-31
Eligibility
Age: 4 Years
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheffield Children's NHS Foundation Trust
Principal Investigators:
  • Judith Gilchrist (PRINCIPAL_INVESTIGATOR) - Sheffield Children's NHS Foundation Trust
Contact Information
Study Contact:
Meena Balasubramanian
0114 3053136
meena.balasubramanian@nhs.net
Gillian Gatenby
0114 3053136
gillian.gatenby@nhs.net
Interventions
  • Drug: dexamethasone oral — The interventions are Dexamethasone, 0.3mg/kg versus 0.6 mg/kg
Study Locations (1 sites)
Sheffield Children's NHS Foundation Trust, Sheffield, S10 2TH United Kingdom
Eligibility Criteria
Inclusion Criteria: * Children aged 4-15 years (inclusive) presenting to the ED with an asthma exacerbation, where oral steroids are recommended by Trust/National guidelines. * Children whose parents/carers do not speak English will also be eligible provided they speak one of the common languages where an interpreter and Information Sheets are available (Slovakian, Arabic and Urdu). Exclusion Criteria: * Children who have been treated with oral or IV steroids in the last 2 weeks. * Hypersensitivity to the study drug. * Children who have concomitant stridor. * First episode of wheezing (not previously diagnosed as asthma). * Children with known difficult asthma who receive longer courses of steroids as standard. * Life threatening episode of asthma. * Children with other conditions that require them to have steroids when unwell. * Children who are involved in current research or have recently been involved in research prior to recruitment
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053
Active, positions filled
Conditions Asthma
Phase PHASE2
Enrollment 307
Locations 133 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.

Primary Outcomes

  • Part A: Change from baseline in the fraction of exhaled nitric oxide (FeNo) (Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Active, positions filled
Start Date: 2025-02-10
Completion: 2027-09-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 307 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Drug: GSK5784283 — GSK5784283 will be administered.
  • Drug: Placebo — Placebo will be administered.
Study Locations (133 sites)
GSK Investigational Site, Little Rock, Arkansas 72205 United States
GSK Investigational Site, Long Beach, California 90815 United States
GSK Investigational Site, Los Angeles, California 90025 United States
GSK Investigational Site, Redding, California 96001 United States
GSK Investigational Site, Riverside, California 92506 United States
GSK Investigational Site, Sacramento, California 95817 United States
GSK Investigational Site, San Jose, California 95117 United States
GSK Investigational Site, Colorado Springs, Colorado 80923 United States
GSK Investigational Site, Lakewood, Colorado 80228-1813 United States
GSK Investigational Site, Wheat Ridge, Colorado 80033 United States
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Informed Consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. The participant must be willing and able to comply with trial and follow-up procedures. * Age: Participants must be 18 to 75 years of age inclusive, at the time of signing the informed consent. * Documented physician-diagnosed asthma for \>= 2 years that meets the National Heart, Lung, and Blood Institute guidelines * Evidence of variable airflow obstruction consistent with asthma. * Documented history of asthma exacerbation within 12 months prior to Visit 1. * An asthma exacerbation defined as a worsening of asthma symptoms. * A well- documented requirement for regular treatment with medium or high-dose ICS for at least 6 months prior to screening. * At least one additional maintenance asthma controller medication is required according to standard practice of care (e.g., long-acting beta 2 agonist (LABA), leukotriene receptors antagonists (LTRA), theophylline, long-acting muscarinic antagonist (LAMA), chromones, etc.). Use of additional asthma controller medications must be documented for at least 3 months prior to Visit 1. * Weight \>=40 kg. * Male or eligible Female. * Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential (WONCBP) OR * Is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1%, 28 days prior to the 1st dose of the study drug and during the study intervention period and follow-up period. The investigator should evaluate potential for contraceptive method failure (e.g. non-compliance, recently initiated) in relationship to the first dose of study intervention. * A WOCBP must have a negative serum pregnancy test at screening and a highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours before each dose of study intervention. * If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Contraceptive use by women should be consistent with location regulations regarding the methods of highly effective contraception for those participating in clinical trials. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., current upper or lower respiratory tract infection, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome, primary ciliary dyskinesia). Helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy. * Active or latent tuberculosis: * Participants with a diagnosis or evidence of active or latent tuberculosis are excluded from the study. * Diagnosis of vocal cord dysfunction, dysfunctional breathing, or pseudo steroid resistant asthma. * Malignancy: A current malignancy or previous history of cancer in remission for less than 5 years prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded). * History of an unresolved clinically significant infection within 30 days prior to Visit 1. * A known immunodeficiency (e.g. human immunodeficiency virus - HIV), other than that explained by the use of corticosteroids taken as therapy for asthma. * Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, rheumatologic, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment including eosinophilic conditions such as hyper-eosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). * Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs at Visit 2 which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study. * Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to Visit 1, whichever is longer and up until the end of study. * Receipt of any investigational non-biologic agent within 30 days or 5 half-lives prior to screening, whichever is longer and up until the end of study. * Experimental vaccines are not permitted within 30 days prior to randomization and up until the end of the study. * Use of immunosuppressive medication (e.g., methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, systemic (oral) corticosteroids) within 3 months prior to Visit 1 and up until the end of study. * Systemic corticosteroid burst including taper within 15 days prior to Visit 1 or during the screening/run-in period. * Subjects who have not responded to Tezepelumab treatment. * Receipt of live or live attenuated vaccine(s) within 30 days prior to randomization or plans to receive such vaccines up until the end of study. * A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report. * Positive test for hepatitis B virus (HBV) defined as either: 1. positive for hepatitis B surface antigen (HBsAg) OR 2. positive for HBV DNA * Positive Hepatitis C antibody test result. * Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention. * Current smokers (tobacco and marijuana) or former smokers with a smoking history \>=10 pack years and subjects using vaping products, including electronic cigarettes. * History of chronic alcohol or drug abuse within 2 years. * History of severe allergic reaction, anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy. * History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation. * Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations. * Participants who meet the following based on results from sample taken at Visit 2: 1. Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN) 2. Total bilirubin \>1.5x ULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%) 3. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * QTcF \>= 450 msec or QTcF \>= 480 msec for patients with bundle branch block or an abnormal ECG finding that is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator in the 12-Lead ECG central
The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges
NCT07085975
Recruiting
Conditions Chronic Cough (CC), Asthma
Phase PHASE1
Enrollment 33
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.

Primary Outcomes

  • The mean %FEV1 change from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of wheeze measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of chest tightness measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of shortness of breath measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The mean change in oxygen saturations (SpO2) from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The intra-class correlation of measures obtained from repeat ATP cough challenges (Baseline to 1 week)
  • The frequency of adverse events (Baseline to 1 week)
  • Total maximum number of evoked coughs (Emax) by any dose of ATP (Until the end of the ATP cough challenge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-05
Completion: 2026-10-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McMaster University
Contact Information
Study Contact:
Imran Satia, MD PhD
905-525-2100
satiai@mcmaster.ca
Interventions
  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
Study Locations (1 sites)
Respiratory Research Lab, Hamilton, Ontario L8N 3Z5 Canada
Eligibility Criteria
Phase 1: Healthy individuals Inclusion Criteria: Eligible participants in Phase 1 will include healthy adults (≥18 years old) with: 1. Normal spirometry; and 2. No current or past medical history of chronic cough or other respiratory diseases. Exclusion Criteria: We will exclude healthy individuals meeting the following: (1) Are a current or former smoker with a \>5 pack-year history and abstinence ≤6 months; 1. Unable to perform acceptable and reproducible spirometry; 2. Have unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Have had a lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; or 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study. 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Women of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening. Phase 2: Patients with RCC/UCC and mild-steroid naïve asthma Inclusion Criteria: Eligible participants will include adults (≥18 years old) with: 1. RCC/UCC for \>1 year, demonstrated by a normal chest radiograph and no airflow obstruction (FEV1/FVC\>0.7/LLN) with either: 1. Insufficient improvement in cough despite treatment targeting any underlying condition(s) contributing to the cough (RCC); or 2. Cough for which an underlying cause has not been determined despite thorough investigation (UCC). 2. Mild steroid-naïve asthma who demonstrate evidence of a positive screening methacholine (PC20\<16 mg/mL); symptoms of cough, shortness of breath, chest tightness, and wheeze, that, in the opinion of the qualified investigator, are well-controlled; and those have not used inhaled or oral corticosteroids for the past month. Exclusion Criteria: Cohort-specific exclusion criteria include the following: For the RCC/UCC cohort: (1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; For the mild steroid-naïve asthma cohort: 1. Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; 2. History or exacerbation or uncontrolled symptoms within the last month prior to the first study visit; and 3. Use of inhaled or oral corticosteroids within the last month prior to the first study visit. We will exclude participants meeting any of the following criteria from the study: 1. Unable to perform acceptable and reproducible spirometry; 2. Unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study; 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Female participants of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study; 2. Have not been using hormonal birth control for a minimum of 3 months prior to screening.
EmoTIChealth: Promoting Adolescent Health Through a Serious Game.
NCT07212530
Recruiting
Conditions Type 1 Diabetes, Asthma, Allergic Rhinit...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The intervention program targets adolescents between 12 and 16 years of age. The intervention program is designed for adolescents during a critical developmental stage marked by significant life transitions, where building strong personal resources and receiving psychological support is essential to foster socioemotional skills and overall well-being. The serious game aims to promote psycho-emotional health in the general adolescent population, supporting healthy development and preventing future emotional difficulties. At the same time, it incorporates specific modules for adolescents living with chronic conditions such as asthma, food allergy, type 1 diabetes, and allergic rhinitis, who may face additional risks of psychological challenges that can complicate treatment and prognosis. By combining universal health promotion with tailored support, the program addresses both the needs of healthy adolescents and those with chronic illnesses. The platform integrates digital and technological tools for dynamic and personalized intervention. Artificial intelligence adapts activities and feedback to each participant's socio-demographic profile and evolving needs, this supports directly in participants' daily lives and natural environments, making the experience more relevant and impactful. The serious game, proven effective in engaging young people, goes beyond traditional psychoeducation by creating an interactive environment where adolescents develop socio-emotional competencies, resilience, and health-related knowledge. Through its six thematic areas, the game promotes overall well-being and healthy habits, while its condition-specific modules provide targeted guidance and coping strategies for asthma, food allergies, type 1 diabetes, and allergic rhinitis.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: EmoTIChealth — The EmoTIChealth technological platform intervenes in users through a "serious game", i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself. The game is composed of 6 areas, each of which refers to one of the variables that are analyzed or considered important in promoting health related quality of life and adaptation to chronic illness: Area 1. Psychoeducation; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication.

Primary Outcomes

  • Change Quality of Life (Baseline-Pre-Post) (Baseline up to 8 weeks)
  • Change Emotional and Behavioral Problems (Baseline-Pre-Post) (Baseline up to 8 weeks)
  • Change Emotional Competences (Baseline-Pre-Post) (Baseline up to 8 weeks)
  • Change Self-concept (Baseline-Pre-Post) (Baseline up to 8 weeks)
  • Change Coping (Baseline-Pre-Post) (Baseline up to 8 weeks)
  • Change Social Skills (Baseline-Pre-Post) (Baseline up to 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2027-08-30
Eligibility
Age: 12 Years
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Valencia
Collaborators: Universitat Politècnica de València
Principal Investigators:
  • Marián Pérez-Marín, PHD (PRINCIPAL_INVESTIGATOR) - Universitat de Valencia
Contact Information
Study Contact:
Marián Pérez-Marín, PHD
0034 9639
marian.perez@uv.es
Interventions
  • Behavioral: EmoTIChealth — The EmoTIChealth technological platform intervenes in users through a "serious game", i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself. The game is composed of 6 areas, each of which refers to one of the variables that are analyzed or considered important in promoting health related quality of life and adaptation to chronic illness: Area 1. Psychoeducation; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication.
Study Locations (1 sites)
Facultat de Psicología, Valencia, Valencia 46010 Spain
Eligibility Criteria
Inclusion Criteria: * Informed consent by parents/guardians and participants. * Aged between 12 and 16 years old Exclusion Criteria: * No access to internet or new technologies * Not a Spanish speaker.
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
NCT01143480
Recruiting
Conditions Asthma, Atherosclerosis, Metabolic Syndr...
Phase Not Applicable
Enrollment 725
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Background: \- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers. Objectives: \- To examine how specific genes and proteins in blood cells respond to environmental exposures. Eligibility: \- Healthy volunteers between 18 and 45 years of age. Design: * The study will involve one visit of 45 to 60 minutes. * Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking. * Participants will provide a blood sample for research purposes.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • The primary endpoints of this study are for both cell types and will be levels of 6 cytokines [TNF alpha, IL-6, MIP-2, IL-8, MCP-1, and IFN-beta (ELISA)] induced by LPS and by PAM3CSK4 plus baseline cytokine levels (no exposure to LPS or PAM3CSK... (After analysis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2012-07-30
Completion: Ongoing
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 725 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Environmental Health Sciences (NIEHS)
Principal Investigators:
  • Michael B Fessler, M.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Environmental Health Sciences (NIEHS)
Contact Information
Study Contact:
NIEHS Join A Study Recruitment Group
(855) 696-4347
myniehs@nih.gov
Michael B Fessler, M.D.
(984) 287-4081
fesslerm@niehs.nih.gov
Interventions
N/A
Study Locations (1 sites)
NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina 27709 United States
Eligibility Criteria
* INCLUSION CRITERIA: * Male or female 18 years of age or older * Participants must be able to understand and provide written informed consent to participate in the study * Participants must be able to travel to the CRU * Willing and able to fast after midnight the night prior to their study appointment. * Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control). EXCLUSION CRITERIA: * Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil) * Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit * Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor) * Use of immunosuppressants or other immune-modifying drugs \[e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)\], Monoclonal antibodies \[e.g., infliximab (Remicade)\], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone) * Current treatment for cancer with chemotherapy or radiation * Confirmed or suspected immunosuppressive or immunodeficient condition * GI or respiratory Illness within 5 days prior to enrollment visit, including cold or allergies * Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to enrollment visit (for participants who provide a urine specimen, this will be defined by urine cotinine \>200 ng/mL at visit) * Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of ethanol) per day within the last 24 hours prior to the enrollment visit * Body weight \< 50 kg (\<110 lbs) * Temperature \> 37.6 C; blood pressure \< 90/50 mm Hg or \> 170/95 mm Hg; pulse rate \< 50 or \>100 beats/minute * Pregnant or suspected pregnancy * Chronic Kidney Disease The PI may review medication use on a case by case basis and make a medical determination on the participant s eligibility. In these cases, the PI determination will be documented in the participant s chart.
Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
NCT07651891
Recruiting
Conditions Allergic Rhinitis, Asthma (Diagnosis)
Phase PHASE4
Enrollment 40
Locations 2 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-07-30
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls. STUDY OUTLINE The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected. Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline. Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.

Primary Outcomes

  • Total nasal symptom score (TNSS) (Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. TNSS will be assessed at both occasions.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-12-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Lars Olaf Cardell (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet, Division of ENT
Contact Information
Study Contact:
Carl Skröder, MD
+46 41055181
carl.skroder@ki.com
Lars Olaf Cardell, Professor
lars-olaf.cardell@ki.se
Interventions
  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.
Study Locations (2 sites)
Lund University Hospital, Lund, Skåne County 23152 Sweden
Trelleborg Hospital, Trelleborg, Skåne County 23152 Sweden
Eligibility Criteria
Inclusion Criteria The subject has provided written informed consent to participate in the study. * Age 18-50 years. * Moderate-to-severe allergic symptoms upon exposure to dogs. * Dog allergy confirmed by positive specific IgE. * Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC). * Female subjects of childbearing potential must use adequate contraception. * A negative pregnancy test must be obtained prior to enrolment. Exclusion Criteria * Pregnancy or breastfeeding. * Autoimmune or connective tissue disease. * Cardiovascular disease. * Hepatic disease. * Renal disease. * Malignancy. * Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis). * Chronic obstructive or restrictive lung disease. * Treatment with medications that may interfere with the immune response. * Previous immunotherapy or chemotherapy. * Significant chronic disease. * Major metabolic disease. * Alcohol or substance abuse. * Mental or cognitive incapacity that may impair compliance with study procedures. * Known or suspected hypersensitivity to the study product. * Suspected or confirmed bacterial infection. * Clinically relevant allergy to house dust mite. * Current dog ownership. * Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate. * Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.